Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Garcia-Alfonso, P; Garcia-Foncillas, J; Salazar, R; Perez-Segura, P; Garcia-Carbonero, R; Musulen-Palet, E; Cuatrecasas, M; Landolfi, S; Cajal, SRY; Navarro, S.

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & Translational Oncology. 2015; 17(4): 264-273 Nº de citas: 10 [doi:10.1007/s12094-014-1252-0]

Martin, M; Loibl, S; von Minckwitz, G; Morales, S; Martinez, N; Guerrero, A; Anton, A; Aktas, B; Schoenegg, W; Munoz, M; Garcia-Saenz, JA; Gil, M; Ramos, M; Margeli, M; Carrasco, E; Liedtke, C; Wachsmann, G; Mehta, K; De la Haba-Rodriguez, JR.

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(9): 1045 Nº de citas: 99 [doi:10.1200/JCO.2014.57.2388]

Garcia-Gonzalez, X; Cortejoso, L; Garcia, MI; Garcia-Alfonso, P; Robles, L; Gravalos, C; Gonzalez-Haba, E; Marta, P; Sanjurjo, M; Lopez-Fernandez, LA.

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer

Oncotarget. 2015; 6(8): 6422-6430 Nº de citas: 56 [doi:10.18632/oncotarget.3289]

Sotelo, MJ; Sastre, J; Maestro, ML; Veganzones, S; Vieitez, JM; Alonso, V; Gravalos, C; Escudero, P; Vera, R; Aranda, E; Garcia-Alfonso, P; Gallego-Plazas, J; Lopez, C; Pericay, C; Arrivi, A; Vicente, P; Ballesteros, P; Elez, E; Lopez-Ladron, A; Diaz-Rubio, E.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

ANNALS OF ONCOLOGY. 2015; 26(3): 535-541 Nº de citas: 67 [doi:10.1093/annonc/mdu568]

Casla, S; Hojman, P; Marquez-Rodas, I; Lopez-Tarruella, S; Jerez, Y; Barakat, R; Martin, M.

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients

Clinical & Translational Oncology. 2015; 17(3): 180-196 Nº de citas: 47 [doi:10.1007/s12094-014-1184-8]

Tanic, M; Yanowski, K; Gomez-Lopez, G; Rodriguez-Pinilla, MS; Marquez-Rodas, I; Osorio, A; Pisano, DG; Martinez-Delgado, B; Benitez, J.

MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors

INTERNATIONAL JOURNAL OF CANCER. 2015; 136(3): 593-602 Nº de citas: 39 [doi:10.1002/ijc.29021]

Martin, M; Martinez, N; Ramos, M; Calvo, L; Lluch, A; Zamora, P; Munoz, M; Carrasco, E; Caballero, R; Garcia-Saenz, JA; Guerra, E; Caronia, D; Casado, A; Ruiz-Borrego, M; Hernando, B; Ignacio Chacon, J; De la Torre-Montero, JC; Jimeno, MA; Heras, L; Alonso, R; De la Haba, J; Pita, G; Constenla, M; Gonzalez-Neira, A.

Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis

ONCOLOGIST. 2015; 20(2): 111-112 Nº de citas: 19 [doi:10.1634/theoncologist.2014-0379]

Kamieniak, MM; Rico, D; Milne, RL; Munoz-Repeto, I; Ibanez, K; Grillo, MA; Domingo, S; Borrego, S; Cazorla, A; Garcia-Bueno, JM; Hernando, S; Garcia-Donas, J; Hernandez-Agudo, E; Cajal, TRY; Robles-Diaz, L; Marquez-Rodas, I; Cusido, M; Saez, R; Lacambra-Calvet, C; Osorio, A; Urioste, M; Cigudosa, JC; Paz-Ares, L; Palacios, J; Benitez, J; Garcia, MJ.

Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

MOLECULAR ONCOLOGY. 2015; 9(2): 422-436 Nº de citas: 19 [doi:10.1016/j.molonc.2014.09.010]

Mackey, JR; Ramos-Vazquez, M; Lipatov, O; McCarthy, N; Krasnozhon, D; Semiglazov, V; Manikhas, A; Gelmon, KA; Konecny, GE; Webster, M; Hegg, R; Verma, S; Gorbunova, V; Gerges, DA; Thireau, F; Fung, H; Simms, L; Buyse, M; Ibrahim, A; Martin, M.

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(2): 141-38 Nº de citas: 101 [doi:10.1200/JCO.2014.57.1513]

Pineda, S; Gomez-Rubio, P; Picornell, A; Bessonov, K; Marquez, M; Kogevinas, M; Real, FX; Van Steen, K; Malats, N.

Framework for the Integration of Genomics, Epigenomics and Transcriptomics in Complex Diseases

HUMAN HEREDITY. 2015; 79(3-4): 124-136 Nº de citas: 17 [doi:10.1159/000381184]

Martin, M; Herrero, A; Echavarria, I.

BREAST CANCER

ARBOR-CIENCIA PENSAMIENTO Y CULTURA. 2015; 191(773): Nº de citas: 8 [doi:10.3989/arbor.2015.773n3004]

Martinez-Laperche, C; Noriega, V; Kwon, M; Balsalobre, P; Gonzalez-Rivera, M; Serrano, D; Anguita, J; Gayoso, J; Diez-Martin, JL; Buno, I.

Achievement of early complete donor chimerism in CD25(+)-activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation

EXPERIMENTAL HEMATOLOGY. 2015; 43(1): 4-13 Nº de citas: 4 [doi:10.1016/j.exphem.2014.09.003]

Rosmarin, D; Palles, C; Pagnamenta, A; Kaur, K; Pita, G; Martin, M; Domingo, E; Jones, A; Howarth, K; Freeman-Mills, L; Johnstone, E; Wang, HT; Love, S; Scudder, C; Julier, P; Fernandez-Rozadilla, C; Ruiz-Ponte, C; Carracedo, A; Castellvi-Bel, S; Castells, A; Gonzalez-Neira, A; Taylor, J; Kerr, R; Kerr, D; Tomlinson, I.

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

GUT. 2015; 64(1): 111-120 Nº de citas: 94 [doi:10.1136/gutjnl-2013-306571]

De las Penas, R; Escobar, Y; Henao, F; Blasco, A; Rodriguez, CA.

SEOM guidelines on hydroelectrolytic disorders

Clinical & Translational Oncology. 2014; 16(12): 1051-1059 Nº de citas: 14 [doi:10.1007/s12094-014-1234-2]

Martin, AJM; Puig, CF; Martin, LMN; Garcia, PB; Jimenez, MM.

Clinical guide SEOM on venous thromboembolism in cancer patients

Clinical & Translational Oncology. 2014; 16(12): 1079-1090 Nº de citas: 21 [doi:10.1007/s12094-014-1238-y]

Saura, C; Garcia-Saenz, JA; Xu, BH; Harb, W; Moroose, R; Pluard, T; Cortes, J; Kiger, C; Germa, C; Wang, KM; Martin, M; Baselga, J; Kim, SB.

Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. 2014; 32(32): 3626 Nº de citas: 114 [doi:10.1200/JCO.2014.56.3809]

Prat, A; Lluch, A; Albanell, J; Barry, WT; Fan, C; Chacon, JI; Parker, JS; Calvo, L; Plazaola, A; Arcusa, A; Segui-Palmer, MA; Burgues, O; Ribelles, N; Rodriguez-Lescure, A; Guerrero, A; Ruiz-Borrego, M; Munarriz, B; Lopez, JA; Adamo, B; Cheang, MCU; Li, Y; Hu, Z; Gulley, ML; Vidal, MJ; Pitcher, BN; Liu, MC; Citron, ML; Ellis, MJ; Mardis, E; Vickery, T; Hudis, CA; Winer, EP; Carey, LA; Caballero, R; Carrasco, E; Martin, M; Perou, CM; Alba, E.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

BRITISH JOURNAL OF CANCER. 2014; 111(8): 1532-1541 Nº de citas: 109 [doi:10.1038/bjc.2014.444]

Martorell, PM; de las Heras, BB; Perez-Fidalgo, JA; Alvaro, MH; Martin, M; Albanell, J; Hernandez, AL.

Subcutaneous trastuzumab: drug development and current position

Clinical & Translational Oncology. 2014; 16(10): 859-864 Nº de citas: 2 [doi:10.1007/s12094-014-1181-y]